Bisphosphonate modulates morphological and mechanical properties in distraction osteogenesis through inhibition of bone resorption

Bone

Volumn 39, Issue 3, 2006, Pages 573-581

  Takahashi, Mitsuhiko ^a   Yukata, Kiminori ^a   Matsui, Yoshito ^a   Abbaspour, Aziz ^a   Takata, Shinjiro ^a   Yasui, Natsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Bisphosphonate; Bone resorption; Bone strength; Distraction osteogenesis; Morphological modulation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; MINODRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE REGENERATION; CELL STRUCTURE; CONTROLLED STUDY; DISTRACTION OSTEOGENESIS; DRUG EFFICACY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; QUANTITATIVE ANALYSIS; TIBIA;

ANIMALS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; DENSITOMETRY, X-RAY; DIPHOSPHONATES; MALE; OSTEOGENESIS; RABBITS;

EID: 33746609766     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.03.010     Document Type: Article

References (47)

1. Green S.A., Jackson J.M., Wall D.M., Marinow H., and Ishkanian J. Management of segmental defects by the Ilizarov intercalary bone transport method. Clin. Orthop. Relat. Res. 280 (1992) 136-142
2. Cattaneo R., Catagni M., and Johnson E.E. The treatment of infected nonunions and segmental defects of the tibia by the methods of Ilizarov. Clin. Orthop. Relat. Res. 280 (1992) 143-152
3. Paley D., Catagni M., Argnani F., Prevot J., Bell D., and Armstrong P. Treatment of congenital pseudoarthrosis of the tibia using the Ilizarov technique. Clin. Orthop. Relat. Res. 280 (1992) 81-93
4. Dendrinos G.K., Kontos S., and Lyritsis E. Use of the Ilizarov technique for treatment of non-union of the tibia associated with infection. J. Bone Jt. Surg., Am. 77 6 (1995) 835-846
5. Tsuchiya H., Abdel-Wanis M.E., Sakurakichi K., Yamashiro T., and Tomita K. Osteosarcoma around the knee. Intraepiphyseal excision and biological reconstruction with distraction osteogenesis. J. Bone Jt. Surg., Br. 84 8 (2002) 1162-1166
6. Ilizarov G.A. The tension-stress effect on the genesis and growth of tissues: Part I. The influence of stability of fixation and soft-tissue preservation. Clin. Orthop. Relat. Res. 238 (1989) 249-281
7. Ilizarov G.A. The tension-stress effect on the genesis and growth of tissues: Part II. The influence of the rate and frequency of distraction. Clin. Orthop. Relat. Res. 239 (1989) 263-285
8. Sato M., Yasui N., Nakase T., Kawahata H., Sugimoto M., Hirota S., et al. Expression of bone matrix proteins mRNA during distraction osteogenesis. J. Bone Miner. Res. 13 8 (1998) 1221-1231
9. Sato M., Ochi T., Nakase T., Hirota S., Kitamura Y., Nomura S., et al. Mechanical tension-stress induces expression of bone morphogenetic protein (BMP)-2 and BMP-4, but not BMP-6, BMP-7, and GDF-5 mRNA, during distraction osteogenesis. J. Bone Miner. Res. 14 7 (1999) 1084-1095
10. Okazaki H., Kurokawa T., Nakamura K., Matsushita T., Mamada K., and Kawaguchi H. Stimulation of bone formation by recombinant fibroblast growth factor-2 in callotasis bone lengthening of rabbits. Calcif. Tissue Int. 64 6 (1999) 542-546
11. Stewart K.J., Weyand B., van't Hof R.J., White S.A., Lvoff G.O., Maffulli N., et al. A quantitative analysis of the effect of insulin-like growth factor-1 infusion during mandibular distraction osteogenesis in rabbits. Br. J. Plast. Surg. 52 5 (1999) 343-350
12. Rauch F., Lauzier D., Travers R., Glorieux F., and Hamdy R. Effects of locally applied transforming growth factor-beta1 on distraction osteogenesis in a rabbit limb-lengthening model. Bone 26 6 (2000) 619-624
13. Li G., Bouxsein M.L., Luppen C., Li X.J., Wood M., Seeherman H.J., et al. Bone consolidation is enhanced by rhBMP-2 in a rabbit model of distraction osteogenesis. J. Orthop. Res. 20 4 (2002) 779-788
14. Eckardt H., Bundgaard K.G., Christensen K.S., Lind M., Hansen E.S., and Hvid I. Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF-inhibitor to the rabbit tibia during distraction osteogenesis. J. Orthop. Res. 21 2 (2003) 335-340
15. Hamdy R.C., Amako M., Beckman L., Kawaguchi M., Rauch F., Lauzier D., et al. Effects of osteogenic protein-1 on distraction osteogenesis in rabbits. Bone 33 2 (2003) 248-255
16. Rauch F., Lauzier D., Croteau S., Travers R., Glorieux F.H., and Hamdy R. Temporal and spatial expression of bone morphogenetic protein-2, -4, and -7 during distraction osteogenesis in rabbits. Bone 27 3 (2000) 453-459
17. Pacicca D.M., Patel N., Lee C., Salisbury K., Lehmann W., Carvalho R., et al. Expression of angiogenic factors during distraction osteogenesis. Bone 33 6 (2003) 889-898
18. Kojimoto H., Yasui N., Goto T., Matsuda S., and Shimomura Y. Bone lengthening in rabbits by callus distraction. The role of periosteum and endosteum. J. Bone Jt. Surg., Br. 70 4 (1988) 543-549
19. Riggs B.L., and Parfitt A.M. Drugs used to treat osteoporosis. the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 2 (2005) 177-184
20. Smith E.J., McEvoy A., Little D.G., Baldock P.A., Eisman J.A., and Gardiner E.M. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J. Bone Miner. Res. 19 10 (2004) 1698-1705
21. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J. Bone Miner. Res. 18 7 (2003) 1300-1307
22. Little D.G., Cornell M.S., Hile M.S., Briody J., Cowell C.T., and Bilston L. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis. Injury 32 Suppl. 4 (2001) SD14-SD20
23. Little D.G., Cornell M.S., Briody J., Cowell C.T., Arbuckle S., and Cooke-Yarborough C.M. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J. Bone Jt. Surg., Br. 83 7 (2001) 1069-1074
24. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry. standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 6 (1987) 595-610
25. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 4th ed. (2000), San Diego Academic
26. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 2 (2001) 235-242
27. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J. Bone Miner. Res. 13 6 (1998) 1011-1022
28. Sasaki A., Kitamura K., Alcalde R.E., Tanaka T., Suzuki A., Etoh Y., et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int. J. Cancer 77 2 (1998) 279-285
29. Miwa S., Mizokami A., Keller E.T., Taichman R., Zhang J., and Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 65 19 (2005) 8818-8825
30. Cadet E.R., Gafni R.I., McCarthy E.F., McCray D.R., Bacher J.D., Barnes K.M., et al. Mechanisms responsible for longitudinal growth of the cortex. coalescence of trabecular bone into cortical bone. J. Bone Jt. Surg., Am. 85-A 9 (2003) 1739-1748
31. Martin T.J., and Ng K.W. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J. Cell. Biochem. 56 3 (1994) 357-366
32. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137 8 (1996) 2187-2190
33. Kaneko H., Arakawa T., Mano H., Kaneda T., Ogasawara A., Nakagawa M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27 4 (2000) 479-486
34. Kawaguchi H., Chikazu D., Nakamura K., Kumegawa M., and Hakeda Y. Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures. J. Bone Miner. Res. 15 3 (2000) 466-473
35. Tenenbaum H.C., Torontali M., and Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13 3 (1992) 249-255
36. Giuliani N., Pedrazzoni M., Negri G., Passeri G., Impicciatore M., and Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22 5 (1998) 455-461
37. Giuliani N., Pedrazzoni M., Passeri G., Negri G., Impicciatore M., and Girasole G. Bisphosphonates stimulate the production of basic fibroblast growth factor and the formation of bone marrow precursors of osteoblasts. New findings about their mechanism of action. Minerva Med. 89 7-8 (1998) 249-258
38. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 60 21 (2000) 6001-6007
39. Pan B., To L.B., Farrugia A.N., Findlay D.M., Green J., Gronthos S., et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34 1 (2004) 112-123
40. Schindeler A., and Little D.G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem. Biophys. Res. Commun. 338 2 (2005) 710-716
41. Aronson J. Modulation of distraction osteogenesis in the aged rat by fibroblast growth factor. Clin. Orthop. Relat. Res. 425 (2004) 264-283
42. Little D.G., McDonald M., Bransford R., Godfrey C.B., and Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J. Bone Miner. Res. 20 11 (2005) 2044-2052
43. Hoffman A., Stepensky D., Ezra A., Van Gelder J.M., and Golomb G. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int. J. Pharm. 220 1-2 (2001) 1-11
44. Body J.J., Diel I., and Bell R. Profiling the safety and tolerability of bisphosphonates. Semin. Oncol. 31 5 Suppl. 10 (2004) 73-78
45. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws. A growing epidemic. J. Oral Maxillofac. Surg. 61 9 (2003) 1115-1117
46. Amanat N., Brown R., Bilston L.E., and Little D.G. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J. Orthop. Res. 23 5 (2005) 1029-1034
47. Li J., Mori S., Kaji Y., Kawanishi J., Akiyama T., and Norimatsu H. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J. Bone Miner. Res. 15 10 (2000) 2042-2051